Objective:

To compare the efficacy and safety of vancomycin with alternative anti-MRSA agents in adult patients with microbiologically confirmed MRSA skin and soft tissue infections (SSTIs), highlighting the clinical significance of this comparison.

Key Findings:

• Vancomycin remains a standard treatment but has limitations such as nephrotoxicity and reduced efficacy against some MRSA strains, with specific data indicating a need for alternative therapies.
• Alternative agents show improved pharmacokinetics and safety profiles, potentially offering advantages over vancomycin, as evidenced by recent clinical trials.
• The analysis included 39 RCTs, providing a comprehensive comparison of treatment outcomes, with statistical significance noted in several key areas.

Interpretation:

The findings suggest that while vancomycin is effective, newer anti-MRSA agents may offer better outcomes in terms of efficacy and safety for MRSA-associated SSTIs, warranting further investigation into their clinical application.

Limitations:

• Existing evidence is fragmented and inconsistent due to heterogeneity in study designs and outcomes, which may skew the overall effectiveness of treatments.
• Potential publication bias and risk of bias in included studies may affect the reliability of conclusions, particularly in underrepresented populations.

Conclusion:

This meta-analysis provides a clearer understanding of the comparative effectiveness of vancomycin and alternative treatments for MRSA SSTIs, highlighting the need for careful consideration of treatment options in clinical practice.